In this study, we focused on a systematic assessment of the TMB, expressed neoantigens, and the tumor immune microenvironment in both IDH-wildtype and IDH-mutant gliomas, which have distinct tumor biology. This evidence concerns the gene IDH2 and central nervous system cancer.